Aiosyn Introduces Kidney AI Platform
Aiosyn, a medical software company specializing in AI-powered pathology solutions, has announced the release of an AI kidney suite. Leveraging deep learning technology, this solution provides biopharma and research organizations with powerful tools for analyzing kidney structures and quantifying lesions that impact kidney health.
In a press release, Patrick de Boer, CEO of Aiosyn commented, "The platform will enable researchers to identify new and existing CKD biomarkers to study specific patient subgroups. With these new algorithms and AI capabilities we provide CKD researchers with new tools to complement existing biomarker projects and help to advance CKD precision medicine."
Aiosyn's kidney AI suite utilizes AI-powered computational pathology algorithms to objectively quantify kidney lesion scores, offering an opportunity to enhance reproducibility and accelerate drug development. The platform addresses the limitations of the Banff classification currently used in renal biopsy analysis, which suffers from observer variability and relies on qualitative assessments.
Aiosyn’s kidney AI suite facilitates the identification and characterization of pathological processes, presenting a promising avenue for substantial improvements in CKD research and clinical trials. Alongside its kidney AI platform, Aiosyn is actively developing deep learning algorithms for the detection of cancer biomarkers.
Reference
Aiosyn Introduces Kidney AI Platform to Revolutionize Renal Disease Research. (2023, September 18). Business Wire.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
